In Brief This Week: Quest Diagnostics, Solstas Lab, Summit Health; Venaxis; MolecularHealth; ValueOptions, Genomind | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it completed its acquisition of full-service commercial laboratory firm Solstas Lab Partners Group and its subsidiaries for $570 million. In connection with the deal, Quest raised its guidance for full-year 2014. Revenues are now expected to grow between 2 percent and 4 percent, compared to full-year 2013. It previously said 2014 revenue was anticipated to be flat to down 2 percent year over year, excluding the Solstas purchase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."